Thursday, March 07, 2019 9:11:09 PM
While I think the facts regarding MTNB speak for themselves, your posts include no facts, and constitute nothing more than factless cheerleading.
So while I agree with your conclusion that MTNB is undervalued, I don't think is is necessary or helpful to post endless emails that do not show why MTNB is such a great company, that I believe it is.
If you persist in robo-posting, I would respectfully suggest you bolster your optimistic projections with facts, of which there are many.
LM
Recent MTNB News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 12:56:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 01:39:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:07:14 PM
- Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/14/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:01:41 PM
- Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:06:55 PM
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:01:52 PM
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Matinas BioPharma Prices $10 Million Registered Direct Offering • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response • GlobeNewswire Inc. • 03/22/2024 01:15:00 PM
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 03/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:05:14 PM
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 12:35:32 PM
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM